Medical Condition News

RSS

MGH research sheds light on mechanisms of action of mindfulness-based training

Participating in an 8-week mindfulness meditation program appears to make measurable changes in brain regions associated with memory, sense of self, empathy and stress. In a study that will appear in the January 30 issue of Psychiatry Research: Neuroimaging, a team led by Massachusetts General Hospital researchers report the results of their study, the first to document meditation-produced changes over time in the brain's grey matter.

24 Jan 2011

Eckert & Ziegler receives European Commission's indefinite approval for YTTRIGA

Eckert & Ziegler Strahlen- und Medizintechnik AG, a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five years ago the European Medicines Agency EMA approved this drug for the first time and as a result of the current renewal process the drug has now been granted an indefinite approval.

24 Jan 2011

Welch Allyn to feature new suite of devices at 2011 Arab Health Congress in Dubai, UAE

Welch Allyn, a leading global provider of medical products and solutions, will showcase its newest suite of devices that capture, format and transmit vital signs from the point of care to electronic medical records this week at the 2011 Arab Health Exhibition & Congress in Dubai, UAE.

24 Jan 2011

Functional tests are necessary to understand human disease despite genetic sequencing

Despite what you might have heard, genetic sequencing alone is not enough to understand human disease. Researchers at Duke University Medical Center have shown that functional tests are absolutely necessary to understand the biological relevance of the results of sequencing studies as they relate to disease, using a suite of diseases known as the ciliopathies which can cause patients to have many different traits.

24 Jan 2011

China Shenghuo's Lixuwang product recieves Chinese Well-Known Trademark Honor

China Shenghuo Pharmaceutical Holdings, a China-based pharmaceutical company engaged in the research, development, manufacture, and marketing of Traditional Chinese Medicine, nutritional supplement and cosmetic products, today announced that "Lixuwang", the trademark of its best selling product, Xuesaitong Capsule, was awarded the Chinese Well-Known Trademark Honor by the State Administration for Industry and Commerce of China.

24 Jan 2011

CT scans can help physicians to diagnose abdominal pain, reduce health care costs

The use of CT scanning to evaluate abdominal pain in emergency departments can help physicians arrive at a diagnosis quickly and decisively. A study conducted at Massachusetts General Hospital and appearing in the February issue of the American Journal of Roentgenology also finds that information provided by CT scans changed treatment plans for almost half the patients studied and significantly reduced probable hospital admissions.

24 Jan 2011

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.

24 Jan 2011

Two studies explore relationship between nutrition and asthma

Asthma is one of the world's most common chronic diseases, affecting as many as 300 million people. It is estimated that by 2025 there could be an additional 100 million people with the disease. This rapid increase in asthma is most likely due to changing environmental or lifestyle factors, and over the last 15 years, changing diet has emerged as a promising contributor. Two studies published in the in the February 2011 issue of the Journal of the American Dietetic Association explore the possible relationship between nutrition and asthma.

24 Jan 2011

Tamoxifen may reduce individual's risk of death from lung cancer: New study

A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual's risk of death from lung cancer.

24 Jan 2011

Researchers identify key player that lead to increased bleeding in diabetes patients with stroke injury

Strokes are a leading cause of mortality and adult disability. Those that involve intracerebral hemorrhage are especially deadly, and there are no effective treatments to control such bleeding. Moreover, diabetes and hyperglycemia are associated with increases in bleeding during hemorrhagic stroke and worse clinical outcomes.

24 Jan 2011

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.

24 Jan 2011

Stusy: HEPA filters may help reduce pollution-related cardiovascular health risks

Using inexpensive air filters may help reduce cardiovascular disease risk that results from exposure to air pollution, according to researchers from Canada, who studied healthy adultsliving in a small community in British Columbia where wood burning stoves are the main sources of pollution.

24 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

CHIL receives $23.7 NIFA grant to prevent young child obesity

The Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region recently received $23.7 in funding from the USDA National Institute for Food and Agriculture.

24 Jan 2011

Novation, Lantheus Medical to distribute ABLAVAR and DEFINITY diagnostic imaging agents

Lantheus Medical Imaging, a worldwide leader in diagnostic medical imaging, today announced a national contract with Novation for ABLAVAR and DEFINITY Vial For Injectable Suspension, providing increased access to these important diagnostic imaging agents for health care providers served by Novation.

23 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

First U.S. implant of RespiCardia System for treatment of sleep apnea

Cardiac Concepts, announced today the first U.S. clinical implant of the RespiCardia System at The Ohio State University Medical Center, Columbus, Ohio.

21 Jan 2011

Mutation of microRNA miR-96 causes deafness

New research from the University of Sheffield has revealed that the molecular mechanism underlying deafness is caused by a mutation of a specific microRNA called miR-96. The discovery could provide the basis for treating progressive hearing loss and deafness.

21 Jan 2011

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).

21 Jan 2011

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine, extended median overall survival.

21 Jan 2011

Medical Condition News

MGH research sheds light on mechanisms of action of mindfulness-based training

Eckert & Ziegler receives European Commission's indefinite approval for YTTRIGA

Welch Allyn to feature new suite of devices at 2011 Arab Health Congress in Dubai, UAE

Functional tests are necessary to understand human disease despite genetic sequencing

China Shenghuo's Lixuwang product recieves Chinese Well-Known Trademark Honor

CT scans can help physicians to diagnose abdominal pain, reduce health care costs

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

Two studies explore relationship between nutrition and asthma

Tamoxifen may reduce individual's risk of death from lung cancer: New study

Researchers identify key player that lead to increased bleeding in diabetes patients with stroke injury

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

Stusy: HEPA filters may help reduce pollution-related cardiovascular health risks

CRI, Oncovir sign new investment agreement to produce immunological stimulant

CHIL receives $23.7 NIFA grant to prevent young child obesity

Novation, Lantheus Medical to distribute ABLAVAR and DEFINITY diagnostic imaging agents

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

First U.S. implant of RespiCardia System for treatment of sleep apnea

Mutation of microRNA miR-96 causes deafness

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News